Pfizer Deal History & Licensing Activity
Pfizer is a large pharma headquartered in US. Over the past three years, Pfizer has been involved in 31 licensing and acquisition transactions, with a primary focus on Bispecific Antibodies (9 deals). The company currently has 50 active clinical trials, primarily in Solid Tumors.
Deals (12mo)
2
Active Trials
50
Top Modality
Bispecific Antibodies
Focus Area
Solid Tumors
Pfizer Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Pfizer in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| bispecific immuno-oncology assets | 3SBio | Bispecific Antibodies | Unknown | option | Jul 18, 2026 |
| SSGJ-707 (PD-1/VEGF bispecific) | 3SBio / Shenyang Sunshine | Bispecific Antibodies | Unknown | license | Jul 12, 2026 |
| Innovent cancer drugs | Innovent Biologics | Antibodies | Unknown |
Pfizer Pipeline Focus
Therapeutic areas and modalities where Pfizer is most active based on deal history and clinical trial data.
Therapeutic Areas
Pfizer Strategic Signals
Key indicators of Pfizer's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Revenue at Risk (LOE)
Patent expirations create urgency for Pfizer to replace revenue through in-licensing or acquisitions.
Strategic Profile
Acquisition Appetite
Pfizer Clinical Pipeline
Pfizer has 50 active clinical trials across 5 development phases.
14
Unknown
3
Not Applicable
13
Phase 1
10
Phase 2
10
Phase 3
See How Your Asset Matches Pfizer's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Solid Tumors assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Bispecific Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for bispecific antibodies deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Pfizer Licensing & Deal Activity
Pfizer is a large pharma company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 31 deals over the past three years, Pfizer ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Pfizer include Solid Tumors (15 deals and trials), Oncology (9 deals and trials), Metabolic (7 deals and trials), and Infectious Disease (6 deals and trials). In terms of modality, Pfizer has shown particular interest in bispecific antibodies, antibodies, other.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Pfizer and 850+ other biopharma companies. Use our Solidus to benchmark your asset against Pfizer's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.